Fidelity’s FHLC covers more than 300 healthcare stocks, while VanEck’s BBH focuses on about two dozen biotech and life-sciences companies. BBH led over one year, but FHLC had stronger five-year growth, a smaller maximum drawdown and lower fees (0.08% vs. 0.35%).
FHLC grew a hypothetical $1,000 to $1,320 over five years, compared with $1,125 for BBH; their five-year maximum drawdowns were 17.7% and 39.9%, respectively. The comparison table lists trailing one-year returns of 25.99% for FHLC and 45.03% for BBH, but the article’s opening summary gives BBH’s one-year gain as 40.5%.
FHLC had $3.5 billion in assets under management, versus $469.4 million for BBH. About 24% of FHLC is invested in biotech, and its trailing dividend yield is 1.23%, compared with 0.40% for BBH.
